SmokeScreen has been used successfully in a number of randomised controlled trials.

A study into smoking in pregnancy found self-reported smoking habit reported to the midwives was incorrect, with denial amounting to 10.3%, with a further 38.4% significantly under-reported their cigarette consumption.

The feedback from the test contributed to a fall in smoking, with 16% giving up, and 33% significantly reducing their cigarette consumption. In the intervention group, there was a significant fall in nicotine intake, as reflected by a fall in SmokeScreen results. Many women who reported continuing their usual smoking habit throughout pregnancy had a significantly lower test result at the end of pregnancy, suggesting a reduced nicotine intake. In the control group only 8% reported stopping and 23% reducing their cigarette consumption. A high proportion (42%) were shown to increase their smoking towards the end of pregnancy. Combined smoking test results at 36 weeks correlated significantly with birth weight and body length.

SmokeScreen results were shown to be more closely related to the physiological effects of smoking than reported cigarette consumption. Changes to the white cells and contents of blood were correlated to the test results, whereas generally they were not related to self-report (Nic & Tob Res paper)

Nicotine replacement therapy (NRT) is used to improve smoking cessation counselling. SmokeScreen has been used to monitor baseline smoking, which provides useful information to tailor NRT prescribing to the individual smoker's requirements.